## UHS: Universal Health Services, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -4.9% below STRENGTH zone (4.0-10.0%); PEG 1.87 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($213.05)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Invesco Ltd. Raises Holdings in Universal Health Services, Inc. $UHS**
- Source: MarketBeat | 20251207T104511 | Bullish | Relevance: 98%
-  Invesco Ltd. increased its stake in Universal Health Services, Inc. (NYSE:UHS) by 11.1% in the second quarter, reaching 1,461,198 shares valued at approximately $264.7 million. Other institutional investors also modified their holdings, with Norges Bank opening a significant new position. Universal Health Services reported strong quarterly earnings, beating revenue and EPS estimates, while analysts maintain a "Hold" rating with a consensus price target of $234.14.

**2. Cantor Fitzgerald reiterates Overweight rating on Tenet Healthcare stock**
- Source: Investing.com | 20251208T130913 | Neutral | Relevance: 58%
-  Cantor Fitzgerald reiterated its Overweight rating and $245.00 price target on Tenet Healthcare (NYSE:THC), projecting potential outperformance in 2026 for the healthcare provider. The firm highlights THC's attractive valuation compared to competitors and strong financial indicators, including a raised 2025 EBITDA guidance and robust free cash flow. Recent strategic moves like a $2.25 billion notes offering for debt refinancing and a positive outlook revision from Fitch Ratings further underscore the company's solid financial health and growth prospects.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Guggenheim | $274 | $253 | +8% |
| 2025-11-13 | Wells Fargo | $259 | $249 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Guggenheim | main | Buy |
| 2025-11-13 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($11.07M) |
| Sells | 3 ($30.51M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (-3.4%)
- First Eagle Investme: 8.4% (+0.0%)
- Blackrock Inc.: 8.0% (-11.9%)
- State Street Corpora: 4.7% (-3.1%)
- FMR, LLC: 3.8% (+0.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.5% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $31M sold (3 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.87 elevated, pricing in significant growth expectations. Analyst sentiment positive (2 raises, avg +6%). Insider selling cluster ($30.5M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.3B |
| Beta | 1.27 |
| 52W Range | $152.33 - $246.33 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.87 |
| Forward P/E | 9.6 |
| Current P/E | 10.4 |
| YoY Growth | 8.5% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from -2.4% to -4.9% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.9pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.19x) but short-term weakness (below SMA20). MACD histogram bearish (-2.16), momentum weakening. RSI neutral at 46.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.86% (CS: 18) | Weak |
| RSI_14 | 46.5 | Neutral |
| MACD Histogram | -2.16 | Bearish |
| vs SMA20 | 0.972x | Below |
| vs SMA50 | 1.026x | Above |
| vs SMA200 | 1.188x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $225.35
- **Stop Loss:** $213.05 (5.5% risk)
- **Target:** $237.65 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 24
- **Position Value:** $5,408.40
- **Portfolio %:** 5.41%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-25 (Est: $5.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.95 | $5.69 | +14.9% |
| 2025Q2 | $4.96 | $5.35 | +8.0% |
| 2025Q1 | $4.36 | $4.84 | +11.1% |
| 2024Q4 | $4.18 | $4.92 | +17.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*